Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

Virtual R&D Day featuring key opinion leaders and Poseida’s leadership and scientific team members to be held today at 10:00am ET / 7:00am PT SAN DIEGO , Feb. 22, 2023 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of